Literature DB >> 10547147

The type I interferon receptor: structure, function, and evolution of a family business.

K E Mogensen1, M Lewerenz, J Reboul, G Lutfalla, G Uzé.   

Abstract

Recent results indicate that coherent models of how multiple interferons (IFN) are recognized and signal selectively through a common receptor are now feasible. A proposal is made that the IFN receptor, with its subunits IFNAR-1 and IFNAR-2, presents two separate ligand binding sites, and this double structure is both necessary and sufficient to ensure that the different IFN are recognized and can act selectively. The key feature is the duplication of the extracellular domain of the IFNAR-1 subunit and the configurational geometry that this imposes on the intracellular domains of the receptor subunits and their associated tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547147     DOI: 10.1089/107999099313019

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  60 in total

1.  A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.

Authors:  T C Yeh; E Dondi; G Uze; S Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Identifying a role for Toll-like receptor 3 in the innate immune response to Chlamydia muridarum infection in murine oviduct epithelial cells.

Authors:  Wilbert A Derbigny; LaTasha R Shobe; Jasmine C Kamran; Katherine S Toomey; Susan Ofner
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

4.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

5.  Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors.

Authors:  Marta Marchetti; Marie-Noelle Monier; Alexandre Fradagrada; Keith Mitchell; Florence Baychelier; Pierre Eid; Ludger Johannes; Christophe Lamaze
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

6.  Negative regulation of human astrocytes by interferon (IFN) α in relation to growth inhibition and impaired glucose utilization.

Authors:  Ting Wang; Yasuhiro Takikawa; Kei Sawara; Yuichi Yoshida; Kazuyuki Suzuki
Journal:  Neurochem Res       Date:  2012-05-25       Impact factor: 3.996

7.  Distinct evolution of toll-like receptor signaling pathway genes in cetaceans.

Authors:  Ran Tian; Inge Seim; Zepeng Zhang; Ying Yang; Wenhua Ren; Shixia Xu; Guang Yang
Journal:  Genes Genomics       Date:  2019-09-18       Impact factor: 1.839

8.  Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Marshall Behrens; Rebecca Nace; Shruthi Naik; Mark J Federspiel; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2016-09-26       Impact factor: 11.454

9.  Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.

Authors:  Gareth A D Hardy; Scott F Sieg; Benigno Rodriguez; Wei Jiang; Robert Asaad; Michael M Lederman; Clifford V Harding
Journal:  Blood       Date:  2009-03-19       Impact factor: 22.113

10.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.